MedAustron Ion Therapy Center, Austria; Technical University of Vienna, Austria.
MedAustron Ion Therapy Center, Austria.
Radiother Oncol. 2022 Oct;175:73-78. doi: 10.1016/j.radonc.2022.08.008. Epub 2022 Aug 8.
Carbon ion radiotherapy (CIRT) treatment planning is based on relative biological effectiveness (RBE) weighted dose calculations. A large amount of clinical evidence for CIRT was collected in Japan with RBE estimated by the modified microdosimetric kinetic model (MKM) while all European centres apply the first version of the local effect model (LEM). Japanese schedules have been used in Europe with adapted prescription dose and organs at risk (OAR) dose constraints. Recently, less conservative adapted LEM constraints have been implemented in clinical practice. The aim of this study was to analyse the new set of LEM dose constraints for brain parenchyma, brainstem and optic system considering both RBE models and evaluating early clinical data.
31 patients receiving CIRT at MedAustron were analysed using the RayStation v9A planning system by recalculating clinical LEM-based plans in MKM. Dose statistics (D1cm, D5cm, D0.1cm, D0.7cm, D10%, D20%) were extracted for relevant critical OARs. Curve fitting for those values was performed, resulting in linear quadratic translation models. Clinical and radiological toxicity was evaluated.
Based on derived fits, currently applied LEM constraints matched recommended MKM constraints with deviations between -8% and +3.9%. For particular cases, data did not follow the expected LEM vs MKM trends resulting in outliers. Radiological (asymptomatic) toxicity was detected in two outlier cases.
Respecting LEM constraints does not automatically ensure that MKM constraints are met. Constraints for both RBE models need to be fulfilled for future CIRT patients at MedAustron. Careful selection of planning strategies is essential.
碳离子放射治疗(CIRT)的治疗计划基于相对生物效应(RBE)加权剂量计算。在日本,大量的 CIRT 临床证据是通过改良微剂量动力学模型(MKM)估计的 RBE 收集的,而所有欧洲中心都应用第一版局部效应模型(LEM)。日本的方案已在欧洲使用,调整了处方剂量和危及器官(OAR)剂量限制。最近,在临床实践中采用了不那么保守的适应性 LEM 限制。本研究的目的是分析新的 LEM 剂量限制,用于脑实质、脑干和视系统,同时考虑两种 RBE 模型,并评估早期临床数据。
使用 RayStation v9A 计划系统对在 MedAustron 接受 CIRT 的 31 名患者进行分析,通过在 MKM 中重新计算临床 LEM 为基础的计划进行计算。提取相关关键 OAR 的剂量统计数据(D1cm、D5cm、D0.1cm、D0.7cm、D10%、D20%)。对这些值进行曲线拟合,得到线性二次翻译模型。评估临床和放射学毒性。
基于推导的拟合值,目前应用的 LEM 限制与推荐的 MKM 限制相匹配,偏差在-8%至+3.9%之间。对于特殊病例,数据不符合预期的 LEM 与 MKM 趋势,导致出现异常值。在两个异常值病例中检测到放射学(无症状)毒性。
遵守 LEM 限制并不自动确保满足 MKM 限制。未来 MedAustron 的 CIRT 患者需要同时满足两种 RBE 模型的限制。仔细选择规划策略至关重要。